Sort
82,697 grants matching “vaccine development”
A novel vaccine: botulinum neurotoxin subunit on a viral carrier.
$817,599Matthias Johannes Schnell · Molecular Targeting Technologies, Inc. · R42 · FY2012 · AI
St. Jude-Memphis Adolescent Trials Unit
$817,570Aditya H Gaur · St. Jude Children'S Research Hospital · U01 · FY2015 · HD
Trypanosome Transmission Biology in Tsetse
$817,479Serap Aksoy · Yale University · R01 · FY2023 · AI
Core B - Technology Core
$817,413Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · U19 · FY2023 · AI
Containing Bioterrorist and Emerging Infectious Diseases
$817,395M Elizabeth Halloran · Fred Hutchinson Cancer Research Center · U01 · FY2013 · GM
Regulation of Virulence Genes in Bordetella pertussis
$817,353Deborah M Hinton · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2014 · DK
Direct bioelectronic detection of SARS-CoV-2 from saliva using single-molecule field-effect transistor array
$817,335Erik F. Young · Quicksilver Biosciences, Inc. · R44 · FY2021 · DE
A preclinical assessment of monthly intramuscular GSK1265744, an InSTI, as PrEP
$817,211Martin H Markowitz · Aaron Diamond Aids Research Center · R01 · FY2015 · AI
HIV-1 vaccine-elicited antibodies target envelope glycans
$817,205Kevin O Saunders · Duke University · R01 · FY2020 · AI
Mapping spatiotemporal dynamics during enterovirus infection across cells and tissues
$817,205Raul Andino · University Of California, San Francisco · R01 · FY2025 · AI
Bispecific Antibody Therapeutics for Neuroblastoma and Diffuse Midline Glioma
$817,202James M Olson · Seattle Children'S Hospital · U01 · FY2024 · CA
Efficacy of Oral CMV/SIV Vectors
$817,129Louis J. Picker · Oregon Health & Science University · R01 · FY2011 · DE
VACCINATION FOR TREATMENT OF NICTOTINE DEPENDENCE
$817,093Nabi Biopharmaceuticals · U19 · FY2001 · DA
Antibody Responses in Aging SIV Infected Monkeys
$817,006Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2017 · AI
Development of a Sustained Release Injectable Formulation for Long-Term Delivery of ELQs
$816,964Michael Kevin Riscoe · Oregon Health & Science University · R01 · FY2020 · AI
Non-Invasive Plant Virus Particle-Based Anthrax Vaccines
$816,959William Kerr Anderson · Dow Chemical Company · U01 · FY2006 · AI
Strategies for Therapeutic Cancer Vaccine Clinical Trials
$816,925Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Fluorescent nanofoldamers for multiplex flow cytometry
$816,870Christopher J Macnevin · Nirvana Sciences, Inc. · R44 · FY2023 · GM
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antivirals
$816,869Dennis R. Burton · Scripps Research Institute, The · UM1 · FY2020 · AI
Evaluation of Antibody Responses Elicited by Zika Vaccination in Flavivirus-naïve and -experienced Individuals
$816,770Shelly J Krebs · Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2025 · AI
Project 1
$816,691Michel C Nussenzweig · Rockefeller University · P01 · FY2020 · AI
Epitope-focused vaccine strategies against Zika virus
$816,691Michel C Nussenzweig · Rockefeller University · P01 · FY2020 · AI
Immune reconstitution following autologous and allogeneic stem cell transplant
$816,678Frances Hakim · Division Of Basic Sciences - Nci · ZIC · FY2013 · CA
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
$816,677Javier Gordon Ogembo · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Rational design and evaluation of novel mRNA vaccines against MERS-CoV
$816,658Lanying Du · New York Blood Center · R01 · FY2020 · AI